Aduro Biotech Inc. (NASDAQ:ADRO) shot up 3.7% during mid-day trading on Friday . The stock traded as high as $13.11 and last traded at $12.99, with a volume of 150,859 shares trading hands. The stock had previously closed at $12.53.

Several brokerages have issued reports on ADRO. FBR & Co reiterated a “buy” rating on shares of Aduro Biotech in a research report on Friday, April 29th. Canaccord Genuity reiterated a “buy” rating on shares of Aduro Biotech in a research report on Tuesday, May 3rd. Leerink Swann reiterated a “buy” rating and set a $48.00 target price on shares of Aduro Biotech in a research report on Thursday, May 5th. Roth Capital reiterated a “buy” rating and set a $22.00 target price (down from $46.00) on shares of Aduro Biotech in a research report on Monday, May 16th. Finally, Zacks Investment Research lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Monday, March 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $24.17.

The firm’s market capitalization is $852.87 million. The firm has a 50 day moving average price of $11.84 and a 200 day moving average price of $14.32.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Monday, May 2nd. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by $0.20. Equities research analysts predict that Aduro Biotech Inc. will post ($1.24) earnings per share for the current year.

In other news, insider Thomas W. Dubensky sold 25,000 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $11.61, for a total transaction of $290,250.00. Following the completion of the sale, the insider now owns 13,939 shares of the company’s stock, valued at approximately $161,831.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

An institutional investor recently bought a new position in Aduro Biotech stock. ProShare Advisors LLC acquired a new position in shares of Aduro Biotech Inc. (NASDAQ:ADRO) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 51,296 shares of the company’s stock, valued at approximately $1,443,000. ProShare Advisors LLC owned approximately 0.08% of Aduro Biotech as of its most recent SEC filing.

Aduro Biotech, Inc is a clinical-stage immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases. Its technologies are based on live, attenuated, double-deleted Listeria mononcytogenes (LADD) and cyclic dinucleotides (CDNs).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.